Lymphoma is known as the third most common malignancy in children, and its prevalence
and mortality are increasing. Common treatments, including chemotherapy, radiotherapy …

Treatment of elderly patients with lung cancer is significantly hindered by concerns about
treatment tolerability, toxicity and limited clinical trial data in the elderly; potentially giving …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic
T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers …

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024
study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell …

Over the last decade, the therapeutic scenario for advanced non-small-cell lung cancer
(NSCLC) has undergone a major paradigm shift. Immune checkpoint inhibitors (ICIs) have …

Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1)
monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) …

Tumour‐associated macrophages (TAMs) play an important role in the tumour environment
and were reported to be associated with poor prognosis in several tumours. However, the …

Checkpoint inhibitors have revolutionized treatments in modern oncology, including many
conditions previously relegated to palliative therapies only. However, emerging recognition …

Somatic activating mutations in the epidermal growth factor receptor (EGFR) are one of the
most common oncogenic drivers in cancers such as non-small-cell lung cancer (NSCLC) …

Purpose This article explores the efficacy, toxicity, place in therapy, and considerations for
use of recently approved immune checkpoint inhibitors (ICIs) in the treatment of non–small …